Its Stock Has Paid Off Big Time For Humanigen Inc.

Humanigen Inc. (NASDAQ: HGEN) stock fell -2.47% on Monday to $0.15 against a previous-day closing price of $0.15. With 2.38 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.73 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1554 whereas the lowest price it dropped to was $0.1445. The 52-week range on HGEN shows that it touched its highest point at $4.11 and its lowest point at $0.09 during that stretch. It currently has a 1-year price target of $3.22. Beta for the stock currently stands at -0.99.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HGEN was down-trending over the past week, with a drop of -15.25%, but this was up by 36.36% over a month. Three-month performance dropped to -0.53% while six-month performance fell -65.34%. The stock lost -94.25% in the past year, while it has gained 25.00% so far this year. A look at the trailing 12-month EPS for HGEN yields -1.52 with Next year EPS estimates of -0.34. For the next quarter, that number is -0.06. This implies an EPS growth rate of -66.90% for this year and 66.00% for next year. EPS is expected to grow by 12.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 21.90%.

Float and Shares Shorts:

At present, 119.08 million HGEN shares are outstanding with a float of 104.84 million shares on hand for trading. On Oct 13, 2022, short shares totaled 7.16 million, which was 6.91% higher than short shares on Sep 14, 2022. In addition to Dr. Cameron Durrant M.D., MBA as the firm’s Chairman, CEO, Principal Financial & Accounting Officer, Dr. Dale Chappell M.B.A., M.D., MBA serves as its Chief Scientific Officer & Director.

Institutional Ownership:

Through their ownership of 14.71% of HGEN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 14.91% of HGEN, in contrast to 14.88% held by mutual funds. Shares owned by individuals account for 1.44%. As the largest shareholder in HGEN with 10.19% of the stake, Black Horse Capital Management LL holds 12,134,287 shares worth 12,134,287. A second-largest stockholder of HGEN, GSA Capital Partners LLP, holds 1,026,643 shares, controlling over 0.86% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in HGEN, holding 933,874 shares or 0.78% stake. With a 0.57% stake in HGEN, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 683,489 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.23% of HGEN stock, is the second-largest Mutual Fund holder. It holds 273,184 shares valued at 32782.0. iShares Tr. – Micro Cap ETF holds 0.17% of the stake in HGEN, owning 196,644 shares worth 23597.0.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HGEN since 3 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HGEN analysts setting a high price target of $9.00 and a low target of $0.15, the average target price over the next 12 months is $3.22.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. HGEN will report FY 2022 earnings on 02/26/2024. Analysts have provided yearly estimates in a range of -$0.90 being high and -$1.10 being low. For HGEN, this leads to a yearly average estimate of -$1.02. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Humanigen Inc. surprised analysts by -$0.05 when it reported -$0.23 EPS against a consensus estimate of -$0.18. The surprise factor in the prior quarter was -$0.11. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.11. The average estimate for the next quarter is thus -$0.06.

Summary of Insider Activity:

Insiders traded HGEN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 2,107,496 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *